Oncimmune’s proprietary EarlyCDT® cancer detection tests are based on the presence in the blood of autoantibodies against specific tumour associated antigens that have the potential to detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types.
A key ingredient to Oncimmune’s success is its extensive scientific and clinical validation studies. More than 120,000 patient samples were run and 12 million data points analysed to validate the technical and clinical performance of EarlyCDT–Lung. Since then over 150,000 commercial tests have also been run in the US laboratory.
EarlyCDT®–Lung is being used in what is generally acknowledged to be the largest randomised trial for the early detection of lung cancer using biomarkers ever conducted; the National Health Service (NHS) Scotland ECLS study of 12,000 high-risk smokers.1
1 Sullivan FM, Farmer E, Mair FS et al. Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): study protocol for a randomized controlled trial. BMC Cancer 2017;17:187. http://rdcu.be/pZ60